Delving into the Latest Updates on AmCyte, Inc. with Synapse

Overview

Tags

Respiratory Diseases

Infectious Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

BACKGROUNDCellular replacement therapy represents a promising strategy for treating type I diabetes; however, such an approach is limited due to the inadequate availability of human donor tissue. Here we investigated the extent to which human islet tissue can be expanded in monolayer culture and brought back to islet function.METHODSAdult human pancreatic cells were proliferated with a serum-free media in monolayer cultures through multiple passages. Expanded cells were dispersed and encapsulated in alginate-poly-l-lysine microcapsules wherein the cells spontaneously coalesced into islet-like clusters. Encapsulated cell clusters were subsequently transplanted into the peritoneal cavity of streptozotocin-induced diabetic severe combined immunodeficiency mice.RESULTSThe cultured monolayer cells secreted insulin in response to glucose stimulation and maintained endocrine gene expression. Encapsulated islet-like clusters displayed cellular architecture similar to freshly isolated and encapsulated adult human islets maintained in culture, exhibiting an immunoreactive core of insulin, glucagon, and somatostatin, as well as peripheral cytokeratin-19 staining. Encapsulated aggregates significantly reduced hyperglycemia in transplanted mice within 1 week and normoglycemia was achieved after 5 weeks. Human C-peptide was detected in transplanted mice concomitant with the reduction in hyperglycemia. Capsules recovered 8 weeks posttransplantation exhibited insulin immunoreactivity.CONCLUSIONSCollectively, these data indicate that adult human pancreatic islet cells can be expanded by three serial passages while maintaining their endocrine properties and can yield functional islet-like cell clusters through intracapsular aggregation that reverse hyperglycemia in diabetic mice. This culture and aggregation process could serve as a platform for proliferation and differentiation studies of endocrine lineage cells.

1

News (Medical) associated with AmCyte, Inc.

16 Nov 2021

·www.biospace.com

Amcyte Pharma Announces U.S. Launch of Nasitrol® Nasal Spray

Study Publication: Algae-Derived Nasal Spray Effective as Prophylaxis in Reducing COVID Infection Among ICU Staff KIRKLAND, WA – NOVEMBER 16, 2021 -- Amcyte Pharma, a Seattle-based company dedicated to the development of novel pharmaceutical products in immunology, announced the U.S. launch of its Nasitrol® nasal spray for sinus irrigation. In an independent clinical trial published in the peer-reviewed International Journal of General Medicine, Nasitrol reduced COVID transmission among ICU staff by nearly 80%, suggesting it could represent a safe and effective prophylaxis to prevent transmission of COVID-19. Nasitrol is a patented nasal spray based on iota carrageenan, a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as a nasal spray in the treatment of the common cold. The nasal cavity and the rhinopharynx are key sites of the initial replication of SARS-CoV-2. Iota-carrageenan is thought to exert antiviral activity through its interaction with the viral surface, preventing viral entry and capturing viral particles released by infected cells. Nasitrol is designed to reduce the viral load in upper respiratory airways, preventing viruses from proliferating and spreading into the lungs. “We are excited to be commercializing Nasitrol nasal spray, a product that has shown such promise as a prophylaxis against COVID transmission, in addition to vaccination, hand hygiene, use of personal protective equipment and social distancing,” said Dr. Gustavo Mahler, CEO of Amcyte Pharma. The clinical study was conducted at 8 hospital ICUs with a sample of 394 clinically healthy physicians, nurses and other medical professionals who provided care to COVID patients and who had not yet been vaccinated. Study subjects were randomly assigned to receive four daily doses of Nasitrol spray or placebo for 21 days. The incidence of COVID-19 infection, as detected with PCR testing, was significantly lower in the Nasitrol group compared with placebo (1.0% vs 5.0%), a reduction in risk of 79.8%. The study was led by Dr. Juan M. Figueroa of The Cesar Milstein Research Institute in Argentina. Nasitrol is the only nasal spray based on iota carrageenan available in the US. Nasitrol is available through the company’s web site or by contacting the company at (800) 217-0441 or info@nasitrol.com. About Amcyte Pharma Amcyte’s team has over 20 years of experience in pharmaceutical development and manufacturing. The company has built strong partnerships with leading academic institutions and clinical groups to develop novel indications for its portfolio of products. Amcyte’s pipeline includes over-the-counter products with improved therapeutic profiles against existing treatments. For more information, please visit .

Vaccine

100 Deals associated with AmCyte, Inc.

Login to view more data

100 Translational Medicine associated with AmCyte, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

NDA/BLA

1

Login to view more data